Kintor Pharmaceutical Ltd. has announced the completion of enrollment for a long-term human safety trial of their novel tyrosinase inhibitor, KT-939. The study involves 130 subjects and aims to evaluate the safety of topical application of 0.2% KT-939 over 48 consecutive weeks. This trial has received approval from the Ethics Committee of Shanghai Skin Disease Hospital and is led by Professor Tan Yimei. The primary focus is on any adverse skin reactions related to the use of KT-939, which is designed to inhibit melanin production and has demonstrated antioxidant and anti-inflammatory effects. Previous trials have shown favorable efficacy and safety profiles. The results of the current long-term safety trial have not yet been presented.